Fig. 10.
Schematic of neoantigen selection and personalized cancer vaccine formulation. The mutated antigens are selected by whole-exome sequencing, RNA sequencing, and HLA typing. The selected epitopes are synthesized and formulated with other immunomodulators, yielding personalized cancer vaccines. Adapted from [124]. Reprinted with permission from Nature Publishing Group.